Literature DB >> 1538282

Cell-mediated and humoral immune responses in children infected with human immunodeficiency virus during the first four years of life.

W Borkowsky1, M Rigaud, K Krasinski, T Moore, R Lawrence, H Pollack.   

Abstract

OBJECTIVES: To determine whether cell-mediated and humoral immune responses to recall antigens develop in children infected with the human immunodeficiency virus (HIV) and, if so, whether these responses are retained.
METHODS: Children infected with HIV and uninfected children born to mothers infected with HIV were compared with respect to lymphoproliferative responses to recall antigens and protective levels of antibody to bacterial toxoids during the first 4 years of life.
RESULTS: Children infected with HIV who were enrolled in a prospective study of the natural history of the infection were relatively normal (1) in their lymphoproliferative responses to diphtheria toxoid, tetanus toxoid, and Candida, and (2) in their ability to make protective diphtheria and tetanus antitoxins during the first 2 years of life. During the next 2 years, attrition was noted in both lymphoproliferative and humoral responses. Attrition in response was not necessarily correlated with declining numbers of helper T cells.
CONCLUSIONS: These results suggest that both cellular and humoral immune responses develop early in life in most children infected with HIV, while they remain relatively well both clinically and immunologically. Previously reported severe immune deficits in these children were probably attributable to advanced clinical disease when they were first studied.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1538282     DOI: 10.1016/s0022-3476(05)80899-6

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  9 in total

1.  OPV strains circulation in HIV infected infants after National Immunisation Days in Bangui, Central African Republic.

Authors:  Alexandre Manirakiza; Emmanuella Picard; Richard Ngbale; Didier Menard; Ionela Gouandjika-Vasilache
Journal:  BMC Res Notes       Date:  2010-05-18

2.  Safety and immunogenicity of early measles vaccination in children born to HIV-infected mothers in the United States: results of Pediatric AIDS Clinical Trials Group (PACTG) protocol 225.

Authors:  Sulachni Chandwani; Judy Beeler; Hong Li; Susette Audet; Betsy Smith; John Moye; David Nalin; Keith Krasinski
Journal:  J Infect Dis       Date:  2011-07       Impact factor: 5.226

3.  Highly active antiretroviral therapy restores in vitro mitogen and antigen-specific T-lymphocyte responses in HIV-1 perinatally infected children despite virological failure.

Authors:  M Peruzzi; C Azzari; L Galli; A Vierucci; M De Martino
Journal:  Clin Exp Immunol       Date:  2002-05       Impact factor: 4.330

4.  Enteric virus infections and diarrhea in healthy and human immunodeficiency virus-infected children.

Authors:  M B Liste; I Natera; J A Suarez; F H Pujol; F Liprandi; J E Ludert
Journal:  J Clin Microbiol       Date:  2000-08       Impact factor: 5.948

5.  FOXP3+Helios+ Regulatory T Cells, Immune Activation, and Advancing Disease in HIV-Infected Children.

Authors:  Alka Khaitan; Adam Kravietz; Mussa Mwamzuka; Fatma Marshed; Tiina Ilmet; Swalehe Said; Aabid Ahmed; William Borkowsky; Derya Unutmaz
Journal:  J Acquir Immune Defic Syndr       Date:  2016-08-15       Impact factor: 3.731

6.  Impaired immunity to recall antigens and neoantigens in severely immunocompromised children and adolescents during the first year of effective highly active antiretroviral therapy.

Authors:  Mona Rigaud; William Borkowsky; Petronella Muresan; Adriana Weinberg; Phillip Larussa; Terry Fenton; Jennifer S Read; Patrick Jean-Philippe; Elaine Fergusson; Bonnie Zimmer; Dorothy Smith; Joyce Kraimer
Journal:  J Infect Dis       Date:  2008-10-15       Impact factor: 5.226

7.  Timing of HAART defines the integrity of memory B cells and the longevity of humoral responses in HIV-1 vertically-infected children.

Authors:  Simone Pensieroso; Alberto Cagigi; Paolo Palma; Anna Nilsson; Claudia Capponi; Elio Freda; Stefania Bernardi; Rigmor Thorstensson; Francesca Chiodi; Paolo Rossi
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-27       Impact factor: 11.205

8.  Vaccination in HIV-infected Patients.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-06       Impact factor: 3.663

9.  Vaccination in patients with HIV infection.

Authors:  Todd D Gleeson; Mark R Wallace; Sybil A Tasker
Journal:  Curr Infect Dis Rep       Date:  2006-03       Impact factor: 3.663

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.